-
1
-
-
38349190476
-
Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management
-
Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13
-
(2008)
Thromb Haemost
, vol.99
, pp. 4-13
-
-
Stasi, R.1
Evangelista, M.L.2
Stipa, E.3
-
2
-
-
1642546472
-
Management of immune thrombocytopenic purpura in adults
-
Stasi R, Proven D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504-22
-
(2004)
Mayo Clin Proc
, vol.79
, pp. 504-522
-
-
Stasi, R.1
Proven, D.2
-
3
-
-
0033179664
-
The incidence of idiopathic thrombocytopenic purpura in adults increases with age
-
Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13
-
(1999)
Blood
, vol.94
, pp. 909-913
-
-
Frederiksen, H.1
Schmidt, K.2
-
4
-
-
0141763618
-
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients
-
Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74
-
(2003)
Br J Haematol
, vol.122
, pp. 966-974
-
-
Neylon, A.J.1
Saunders, P.W.2
Howard, M.R.3
-
5
-
-
33645356971
-
Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia
-
Stasi R, Amadori S, Osborn J, et al. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006;3:e24
-
(2006)
PLoS Med
, vol.3
-
-
Stasi, R.1
Amadori, S.2
Osborn, J.3
-
6
-
-
0034641010
-
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts
-
Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med 2000;160:1630-8
-
(2000)
Arch Int Med
, vol.160
, pp. 1630-1638
-
-
Cohen, Y.C.1
Djulbegovic, B.2
Shamai-Lubovitz, O.3
-
7
-
-
69249240344
-
The ITP syndrome: Pathogenic and clinical diversity
-
Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511-21
-
(2009)
Blood
, vol.113
, pp. 6511-6521
-
-
Cines, D.B.1
Bussel, J.B.2
Liebman, H.A.3
-
8
-
-
34648836081
-
Definition, diagnosis and treatment of immune thrombocytopenic purpura in adults
-
George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura in adults. Curr Opin Haematol 2007;14:535-56
-
(2007)
Curr Opin Haematol
, vol.14
, pp. 535-556
-
-
George, J.N.1
-
9
-
-
23944470406
-
Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(D) immune globulin intravenous administration for immune thrombocytopenic purpura
-
Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7
-
(2005)
Blood
, vol.106
, pp. 1532-1537
-
-
Gaines, A.R.1
-
10
-
-
84868570501
-
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
-
Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012;120:3670-6
-
(2012)
Blood
, vol.120
, pp. 3670-3676
-
-
Robak, T.1
Windyga, J.2
Trelinski, J.3
-
12
-
-
0037410194
-
Mechanism of action of IVIG and anti-D in ITP
-
Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249-55
-
(2003)
Transfus Apher Sci
, vol.28
, pp. 249-255
-
-
Lazarus, A.H.1
Crow, A.R.2
-
13
-
-
0037410194
-
Mechanism of action of IVIG and anti-D in ITP
-
Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249-55
-
(2003)
Transfus Apher Sci
, vol.28
, pp. 249-255
-
-
Lazarus, A.H.1
Crow, A.R.2
-
14
-
-
0018097191
-
Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes
-
Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood 1978;51:771-9
-
(1978)
Blood
, vol.51
, pp. 771-779
-
-
Handin, R.I.1
Stossel, T.P.2
-
15
-
-
84864542296
-
High dose dexamethasone vs. conventional dose prednisolone in adults with immune thrombocytopenia: A prospective multicenter phase II trial. Amer soc of haem congress [abstract]
-
abstract 3687
-
Bae SH, Ryoo HM, Lee W, et al. High dose dexamethasone vs. conventional dose prednisolone in adults with immune thrombocytopenia: a prospective multicenter phase II trial. Amer Soc of Haem Congress [abstract]. Blood 2010;116:abstract 3687
-
(2010)
Blood
, pp. 116
-
-
Bae, S.H.1
Ryoo, H.M.2
Lee, W.3
-
16
-
-
33747495173
-
Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura
-
Balagué C, Vela S, Targarona EM, et al. Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura. Surg Endosc 2006;20:1208-13
-
(2006)
Surg Endosc
, vol.20
, pp. 1208-1213
-
-
Balagué, C.1
Vela, S.2
Targarona, E.M.3
-
17
-
-
12244303642
-
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)
-
Schwartz J, Leber MD, Gilli S, et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72:94-8
-
(2003)
Am J Hematol
, vol.72
, pp. 94-98
-
-
Schwartz, J.1
Leber, M.D.2
Gilli, S.3
-
18
-
-
13244257208
-
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases
-
Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72-7
-
(2005)
Haematologica
, vol.90
, pp. 72-77
-
-
Vianelli, N.1
Galli, M.2
De Vivo, A.3
-
19
-
-
70449468812
-
Vascular complications after splenectomy for haematological disorders
-
Crary S, Buchanan GR. Vascular complications after splenectomy for haematological disorders. Blood 2009;114:2861-8
-
(2009)
Blood
, vol.114
, pp. 2861-2868
-
-
Crary, S.1
Buchanan, G.R.2
-
20
-
-
84864555317
-
How i treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second line treatment
-
Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second line treatment. Blood 2012;120:960-9
-
(2012)
Blood
, vol.120
, pp. 960-969
-
-
Ghanima, W.1
Godeau, B.2
Cines, D.B.3
-
21
-
-
2042544763
-
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
-
Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9
-
(2004)
Br J Haematol
, vol.125
, pp. 232-239
-
-
Cooper, N.1
Stasi, R.2
Cunningham-Rundles, S.3
-
22
-
-
38649120593
-
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial
-
Kuter D, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
-
(2008)
Lancet
, vol.371
, pp. 395-403
-
-
Kuter, D.1
Bussel, J.B.2
Lyons, R.M.3
-
23
-
-
84856739696
-
Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim: Four European case studies (abstract 0237)
-
Newland A, Cervinek L, Eggermann J, et al. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim: four European case studies (abstract 0237). Haemtologica 2010;96:98
-
(2010)
Haemtologica
, vol.96
, pp. 98
-
-
Newland, A.1
Cervinek, L.2
Eggermann, J.3
-
24
-
-
79952924019
-
Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura
-
Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 734-740
-
-
Stasi, R.1
-
25
-
-
65349094579
-
Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
-
Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009;3:57-62
-
(2009)
Biologics
, vol.3
, pp. 57-62
-
-
Cheung, E.1
Liebman, H.A.2
-
26
-
-
0025772328
-
Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect
-
Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884-93
-
(1991)
Blood
, vol.77
, pp. 1884-1893
-
-
Bussel, J.B.1
Graziano, J.N.2
Kimberly, R.P.3
-
27
-
-
51349161357
-
Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn
-
Kumpel BM. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol 2008;154:1-5
-
(2008)
Clin Exp Immunol
, vol.154
, pp. 1-5
-
-
Kumpel, B.M.1
-
28
-
-
84894017872
-
Intravenous anti-D treatment in immune thrombocytopenic purpura: A randomised, double blind, placebo-controlled trial
-
Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment in immune thrombocytopenic purpura: a randomised, double blind, placebo-controlled trial. Lancet 2009;373:641-8
-
(2009)
Lancet
, vol.373
, pp. 641-648
-
-
Scaradavou, A.1
Woo, B.2
Woloski, B.M.3
-
29
-
-
0141889306
-
Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-a receptor antagonist
-
Coopamah MD, Freedman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-a receptor antagonist. Blood 2003;102:2862-7
-
(2003)
Blood
, vol.102
, pp. 2862-2867
-
-
Coopamah, M.D.1
Freedman, J.2
Semple, J.W.3
-
30
-
-
0034656023
-
Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients
-
Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000;95:2523-9
-
(2000)
Blood
, vol.95
, pp. 2523-2529
-
-
Gaines, A.R.1
-
31
-
-
65349094579
-
Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
-
Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009;3:57-62
-
(2009)
Biologics
, vol.3
, pp. 57-62
-
-
Cheung, E.1
Liebman, H.A.2
-
32
-
-
40449102205
-
A human anti-D monoclonal antibody selected for enhanced FccRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies
-
Beliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FccRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008;41:109-19
-
(2008)
Br J Haematol
, vol.41
, pp. 109-119
-
-
Beliard, R.1
Waegemans, T.2
Notelet, D.3
-
33
-
-
21044436632
-
Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources
-
Neil S, Lipman LR, Jackson LJ, et al. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J 2005;46(3):258-68
-
(2005)
ILAR J
, vol.46
, Issue.3
, pp. 258-268
-
-
Neil, S.1
Lipman, L.R.2
Jackson, L.J.3
-
34
-
-
84866621708
-
Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties
-
Olovnikova NI, Ershler MA, Grigorieva OV, et al. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties. Biochemistry (Moscow) 2012;77:925-33
-
(2012)
Biochemistry (Moscow)
, vol.77
, pp. 925-933
-
-
Olovnikova, N.I.1
Ershler, M.A.2
Grigorieva, O.V.3
-
35
-
-
0030900678
-
Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients
-
Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-700
-
(1997)
Blood
, vol.89
, pp. 2689-2700
-
-
Scaradavou, A.1
Woo, B.2
Woloski, B.M.R.3
|